

CLAIMS

1. A pharmaceutical composition that blocks angiogenesis comprising as active agent at least one substance selected from the group consisting of (i) a nucleic acid molecule of a gene coding for protein IRS-1, a complementary sequence or a fragment thereof and (ii) a molecule which inhibits expression of a nucleic acid molecule according to (i).

2. The pharmaceutical composition according to claim 1, wherein the active agent is at least one nucleotide sequence selected from among the group consisting of SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22 and SEQ ID NO. 23 and SEQ ID NO. 28.

3. The pharmaceutical composition according to claim 1, wherein the molecule which inhibits expression of a nucleic acid molecule coding for protein IRS-1 is an antisense sequence of a coding region of SEQ ID NO. 28 comprising at least twelve contiguous nucleotides or derivatives thereof.

4. The pharmaceutical composition according to claim 1, wherein the molecule which inhibits expression of a nucleic acid molecule of a gene coding for protein IRS-1 is selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22 and SEQ ID NO. 23 or a fragment thereof comprising at least twelve contiguous nucleotides or derivatives thereof.

5. The pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable vehicle.

6. The pharmaceutical composition according to claim 1, which contains about 0.001 mg to about 50 mg of active agent and is in a form capable of subcutaneous, intramuscular, intravenous or transdermal administration.

7. A method of inhibiting angiogenesis comprising administering a pharmaceutically effective amount of the pharmaceutical composition according to claim 1.

8. The method according to claim 7, wherein the active agent is at least one nucleotide sequence selected from among the group consisting of SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23 and SEQ ID NO. 28.

9. The method according to claim 7, wherein the molecule which inhibits expression of a nucleic acid molecule coding for protein IRS-1 is an antisense sequence of a coding region of SEQ ID NO. 28 comprising at least twelve contiguous nucleotides or derivatives thereof.

10. The method according to claim 7, wherein the molecule which inhibits expression of a nucleic acid molecule of a gene coding for protein IRS-1 is selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22 and SEQ ID NO. 23 or a fragment thereof comprising at least twelve contiguous nucleotides or derivatives thereof.

11. The method according to claim 7, which contains about 0.001 mg to about 50 mg of active agent and is in a form capable of subcutaneous, intramuscular, intravenous or transdermal administration.

12. A method of treating retinopathy, rheumatoid arthritis, Crohn's disease, atherosclerosis, hyperstimulation of the ovary, psoriasis, endometritis associated with neovascularization, restenosis due to balloon angioplasty, tissue superproduction due to cicatrization, peripheral vascular disease, hypertension, vascular inflammation, Raynaud's disease and Raynaud's phenomena, aneurysm, arterial restenosis, thrombophlebitis, lymphangitis, lymphedema, tissue cicatrization and repair, ischemia, angina, myocardial infarction, chronic heart disease, congestive heart failure, age-related macular degeneration or osteoporosis comprising administering a pharmaceutically effective amount of the pharmaceutical composition according to claim 1.

13. The method according to claim 12, wherein the active agent is at least one nucleotide sequence selected from among the group consisting of SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23 and SEQ ID NO. 28.

14. The method according to claim 12, wherein the molecule which inhibits expression of a nucleic acid molecule coding for protein IRS-1 is an antisense sequence of a coding region of SEQ ID NO. 28 comprising at least twelve contiguous nucleotides or derivatives thereof.

15. The method according to claim 12, wherein the molecule which inhibits expression of a nucleic acid molecule of a gene coding for protein IRS-1 is selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22 and SEQ ID NO. 23 or a fragment thereof comprising at least twelve contiguous nucleotides or derivatives thereof.

16. The method according to claim 12, which contains about 0.001 mg to about 50 mg of active agent and is in a form capable of subcutaneous, intramuscular, intravenous or transdermal administration.

17. A method of diagnosing pathologies linked to angiogenesis comprising:  
contacting a composition containing an active agent including at least one substance selected from the group consisting of (i) a nucleic acid molecule of a gene coding for protein IRS-1, a complementary sequence or a fragment thereof and (ii) a molecule which inhibits expression of a nucleic acid molecule according to (i) and target cells in a condition sufficient to permit inhibition of IRS-1 gene expression;  
measuring expression of the IRS-1 protein by the cells; and  
comparing expression of the protein measured before and after hybridization to measure inhibition of the expression.

18. The method according to claim 17, wherein the pathologies are selected from the group consisting of retinopathies, rheumatodi arthritis, Crohn's disease, atherosclerosis, hyperstimulation of the ovary, psoriasis, endometritis associated with neovascularization, restenosis due to balloon angioplasty, tissue superproduction due to cicatization, peripheral vascular disease, hypertension, vascular inflammation, Raynaud's disease, Raynaud's phenomena, aneurysm, arterial restenosis, thrombophlebitis, lymphangitis, lymphedema, tissue cicatization and repair, ischemia, angina, myocardial infarction, chronic heart disease, congestive heart failure, age-related macular degeneration and osteoporosis.